VCA meets Q4 forecasts but sees 2014 income dip; Piedmont wins FDA thumbs-up for chewable flea fighter;

> Pet healthcare provider VCA ($WOOF) met fourth-quarter earnings forecasts and reported that its full-year 2014 revenues grew 6.4% year over year to $1.9 billion and its net income fell 1.6% to $140.7 million. Release

> Piedmont Animal Health gained FDA approval for Advantus, a chewable flea medication for dogs. Release

> Banfield Pet Hospital named Vincent Bradley, formerly of Walgreens, its new president and CEO. Release

> Henry Schein ($HSIC) announced that 2014 sales in its animal health group rose 11.5% year over year to $2.9 billion. Release

> ImmuCell ($ICCC) announced that strong sales of its First Defense product to prevent scours in newborn calves drove 2014 sales up 26% to $7.6 million but that the company swung from a $117,000 net profit in 2013 to a net loss of $167,000. Release

> Jaguar Animal Health filed its 9th investigational new drug application with the FDA, for a medicine to treat gastrointestinal disorders in horses and foals. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…